The fourth in our series of Conversations with Portia Combow and living with HS. Thalocan Research Innovations CEO Eric Zudak and Portia discuss the roadblocks she’s encountered with clinical studies. Watch the full webinar/conversation at www.thalocan.com/webinars/.
Why We Built Thalocan: The Forgotten Links in Dermatology Clinical Trials Interview with Eric Zudak, CEO of Thalocan Research Innovations by Ginger Claremohr, Claremohr Writing Co. There’s a moment in every startup story when frustration turns into fuel. For Eric Zudak, founder of Thalocan Research Innovations, that moment came when a global pharmaceutical company called…
Old school paper record keeping is time-consuming with a higher potential for missteps. Avoiding this is just ONE of the many reasons we designed LAMA. A patent-pending, BYOD cloud-based solution, Thalocan’s Lesion Area Mapping Assistant (LAMA) is built on a single concept: improve lesion assessment during dermatologic clinical trials with a streamlined, comprehensive and structured…
Teresa DeHaemer, our Senior Director of Business Strategy shares just a small part of her experience at hashtag#RAD2025 – The Revolutionizing Atopic Dermatitis conference in Nashville, which took place June 6th and 7th. Joined by Tyler White, our Senior Director of Business Development, Thalocan Research Innovations expresses our sincere thanks for all the insight, presentations,…
